The Icahn School of Medicine at Mount Sinai has launched the Center for Ophthalmic Artificial Intelligence and Human Health, the first of its kind in New York and one of the first in the United States.
This week, the Pat Tillman Foundation announced it had selected three students at the Icahn School of Medicine at Mount Sinai to be 2023 Tillman Scholars. The foundation provides scholarship funding to military veterans to pursue higher education and continue their service in the fields of health care, business, law, public service, science, technology, engineering, and mathematics (STEM), education, and the humanities.
Striving to improve organ transplant survival rates, internationally renowned researchers in immunology and bioengineering at the Icahn School of Medicine at Mount Sinai have received $15.1 million from the National Institute of Allergy and Infectious Diseases (NIAID) to lead a novel, five-year multi-center research program that will explore trained immunity—the innate immune system’s ability to remember infections and other insults—as a target for preventing organ transplant rejection.
New five-year award will focus on the effects of environmental exposures on health across the lifespan
Dennis Charney, MD, recognized for advancing understanding and treatment of mood and anxiety disorders
Mount Sinai Health System patients will experience greater access to care, fast identification of symptoms, efficient online search and connection to specialists, and easy appointment scheduling thanks to newly launched Digital Experience tools accessible on their smartphones or computers.
Researchers at the Icahn School of Medicine at Mount Sinai have uncovered a trio of immune cells within tumor niches that are associated with immunotherapy response in hepatocellular carcinoma (HCC). HCC is the primary type of liver cancer and one of the most deadly cancers worldwide.
Men were significantly more vulnerable than women to overdose deaths involving opioid and stimulant drugs in 2020-2021, according to a new study analyzing data from across the United States.
The Mount Sinai Health System’s flagship podcast, Road to Resilience, is returning to the airwaves after a yearlong hiatus, the Health System announced today.
Mount Sinai Health System experts will lead key discussions on women’s health, new paths to treat and prevent brain disease, and closing the gap on health disparities at this year’s Aspen Ideas: Health and Aspen Ideas Festival.
Mount Sinai Health System today hosted a ribbon-cutting ceremony for the newly constructed Mount Sinai-Behavioral Health Center, located at 45 Rivington Street in Lower Manhattan. The $140 million facility—believed to be the largest private investment in mental health care in New York State history—will transform behavioral health care in New York City by serving as a comprehensive “one-stop shop” for mental health care, substance use treatment, and primary care.
In a paper published in the journal Academic Medicine, Mount Sinai Health System authors describe progress on the health system’s Road Map for Action to Address Racism, which was developed to unify, systematize, and accelerate antiracism efforts across one of the largest academic medical centers in New York City.
Mount Sinai researchers have developed an innovative artificial intelligence (AI) model for electrocardiogram (ECG) analysis that allows for the interpretation of ECGs as language. This approach can enhance the accuracy and effectiveness of ECG-related diagnoses, especially for cardiac conditions where limited data is available on which to train. In a study published in the June 6 online issue of npj Digital Medicine DOI: 10.1038/s41746-023-00840-9, the team reported that its new deep learning model, known as HeartBEiT, forms a foundation upon which specialized diagnostic models can be created. The team noted that in comparison tests, models created using HeartBEiT surpassed established methods for ECG analysis.
Sleep medicine experts from the Mount Sinai Health System are presenting new research at SLEEP 2023, the 37th annual meeting of the Associated Professional Sleep Societies running until June 7 in Indianapolis.
Breakthrough study addresses unmet need in the treatment of Crohn’s disease and helps patients into clinical and endoscopic remission
Experts say medication commonly used to treat insomnia may also be a therapeutic option for the condition known as REM sleep behavior disorder
Experts also available for interviews on trending topics and studies
First Mount Sinai cardiologist to hold this prestigious position
Mount Sinai doctors and students will share new insights on prenatal care
The Mount Sinai Health System today held a grand opening of the expansion of the Mount Sinai Brooklyn Ambulatory Infusion Center, a cancer treatment center that brings innovative cancer therapy and clinical trials to residents of southern Brooklyn.
A machine learning-based model that enables medical institutions to predict the mortality risk for individual cardiac surgery patients has been developed by a Mount Sinai research team, providing a significant performance advantage over current population-derived models.
First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic stents, which are currently the standard treatment for heart disease patients undergoing percutaneous coronary intervention (PCI).
Mount Sinai Health System today announced that Crain’s New York Business Journal has named three of its leaders to its 2023 Notable Health Care Leaders list. They are Ashutosh Tewari, MBBS, MCh, Kyung Hyun Kim, MD Professor and Chair of the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai and Surgeon-in-Chief of the new Tisch Cancer Hospital; Pamela Abner, MPA, CPXP, Vice President and Chief Diversity Operations Officer, Mount Sinai Health System; and Scott Lorin, MD, MBA, President of Mount Sinai Brooklyn and Associate Professor of Medicine at Icahn Mount Sinai.
Mount Sinai Health System in New York is opening a personalized concierge care facility at 360 Rosemary in West Palm Beach, Florida.
Eimear Kenny, PhD, had just completed undergrad and was working in her first computational genomics job more than 20 years ago when scientists announced the first (nearly) complete sequencing of the human genome—what was considered at the time to be the fundamental blueprint for all humans. The Human Genome Project aimed to map the entire genome in an effort to accelerate the diagnosis and eventual treatment of common and rare diseases.
As Medicare Advantage plans enroll more and more patients with serious illness, it is not clear how well the plans take care of these patients, Mount Sinai researchers say in a Perspective piece published today in the New England Journal of Medicine.
Findings reveal a previously unknown way in which the brain and immune system talk to each other and may identify a new therapeutic target for MS and other brain disorders.
Mount Sinai Health System celebrated its 38th annual Crystal Party on Thursday, May 4, returning to an in-person event at the Central Park Conservatory Garden after four years.
Applying machine learning models, a type of AI, to data collected passively from wearable devices can identify a patient’s degree of resilience and well-being, according to investigators at the Icahn School of Medicine at Mount Sinai in New York. The findings, reported in the May 2nd issue of JAMIA Open, support wearable devices, such as the Apple Watch®, as a way to monitor and assess psychological states remotely without requiring the completion of mental health questionnaires.
The Mount Sinai Health System Assessment of Music Experiences in Navigating Depression (AMEND Lab) at the Louis Armstrong Center for Music and Medicine has received a grant from the National Endowment for the Arts (NEA) to investigate how music and music therapy can influence mood and alter depression symptoms across vulnerable populations.
Institute, including three new centers, will lead research to foster novel discoveries and explore new treatments for a range of diseases from leukemia to Alzheimer’s disease.
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated in a preclinical study a potential new therapeutic approach to treating the most common form of lung cancer. The strategy involves inhibiting the immune-system molecule TREM2 while enhancing natural killer cells (the so-called protectors of the immune system). It was described in the April 20 online issue of Nature Immunology.
Tisch Cancer Center scientists have developed unique models of the deadliest blood cancer, acute myeloid leukemia (AML), creating a transformative resource to study this cancer and eventually its drug response and drug resistance. The models were described in a late-breaking abstract at the annual meeting of the American Association of Cancer Research and simultaneously published in Blood Cancer Discovery, a journal of the American Association for Cancer Research.
Beth Oliver, DNP, RN, Chief Nurse Executive and Senior Vice President, Cardiac Services, Mount Sinai Health System, has been appointed to the New York Academy of Medicine (NYAM)’s Board of Trustees.
Ana Fernandez-Sesma, PhD, has been appointed Chair of the Department of Microbiology at the Icahn School of Medicine at Mount Sinai. Dr. Fernandez-Sesma will direct all educational and research functions of the Department, while cultivating an academic culture that advances insights into virology, vaccinology, immunology, and microbiology, and encourages innovative approaches to teaching and mentoring.
The Mount Sinai Health System’s esophagectomy program has received a three-star (excellent performance) overall composite score from the Society of Thoracic Surgeons (STS).
The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai will expand its research training program in skin biology with support from a five-year, $1.3 million T32 grant from the National Institutes of Health (NIH) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Mount Sinai Health System has been named one of “America’s Most Innovative Companies 2023” by Fortune magazine.
The Mount Sinai Health System has announced the Growth in Operations, Administrations, and Leadership Society (GOALS), an initiative to increase the representation of Black men at the middle and upper levels of management by creating pathways for career advancement through networking, mentorship, and advancement opportunities. This initiative furthers Mount Sinai’s continuing commitment to growing a diverse workplace and providing equitable care for patients.
Reproductive health experts from the Mount Sinai Health System are presenting research at the 70th Annual Meeting of the Society for Reproductive Investigation (SRI) in Brisbane, Australia from March 21-25.
Using a new computational approach they developed to analyze large genetic datasets from rare disease cohorts, researchers at the Icahn School of Medicine at Mount Sinai and colleagues have discovered previously unknown genetic causes of three rare conditions: primary lymphedema (characterized by tissue swelling), thoracic aortic aneurysm disease, and congenital deafness.
In an effort to expand equitable health care throughout New York City, the Digital and Technology Partners (DTP) department at Mount Sinai Health System is collaborating with The New York Public Library (NYPL) to support access to health services through electronic information or technologies—better known as telehealth—and digital literacy skills.
Two top cancer experts have been named to lead Mount Sinai’s new Tisch Cancer Hospital, which is under development and due to open in 2027. Cardinale B. Smith, MD, PhD, has been appointed Chief Medical Officer for the Tisch Cancer Hospital and Vice President of Cancer Clinical Affairs, and Ash Tewari, MBBS, MCh, has been appointed Surgeon-in-Chief of the Tisch Cancer Hospital.
Researchers have identified two previously unknown genes linked to schizophrenia and newly implicated a third gene as carrying risk for both schizophrenia and autism. Led by the Icahn School of Medicine at Mount Sinai, the multi-center study further demonstrated that the schizophrenia risk conferred by these rare damaging variants is conserved across ethnicities. The study may also point to new therapeutics. The findings were published in the March 13 online issue of Nature Genetics.
A novel type of therapy, known as ANGPTL3 inhibitor therapy, was effective in lowering triglycerides in certain types of patients with severe hypertriglyceridemia (sHTG) who had a prior episode(s) of acute pancreatitis. sHTG is a well-established risk factor for recurrent episodes of acute pancreatitis. These high-risk patients were the focus of a phase 2 study that was led by the Icahn School of Medicine at Mount Sinai and sponsored and funded by Regeneron.
High-dose anticoagulation can reduce deaths by 30 percent and intubations by 25 percent in hospitalized COVID-19 patients who are not critically ill when compared to the standard treatment, which is low-dose anticoagulation.
Breakthrough findings from study led by Mount Sinai researcher could improve outcomes for high-risk patients
The Mount Sinai Health System joined an international task force of 52 hearing experts to develop guidelines and guidance to improve the standard of hearing care for adults. The new Living Guidelines, released today on World Hearing Day, detail best practices for treating and diagnosing hearing loss. One of the nine recommendations includes assessing adults for cochlear implants.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
